Coinbase Global said on Wednesday it had secured approval to offer cryptocurrency futures to U.S. retail customers, scoring a major regulatory win even as it battles a lawsuit from the Securities and Exchange Commission (SEC).
The move will allow Coinbase to offer bitcoin and ether futures directly to eligible U.S. customers. Until now, only its institutional clients could trade in such products.
Coinbase shares climbed 3% to $81.55 after the approval, which was granted by the National Futures Association (NFA), a self-regulatory organization designated by the Commodity Futures Trading Commission (CFTC).
“This is a critical milestone that reaffirms our commitment to operate a regulated and compliant business,” Coinbase said.
The company has openly criticized the SEC, which in a June lawsuit accused Coinbase of operating illegally because it had failed to register as an exchange.
CEO Brian Armstrong has also said more U.S. crypto companies could move offshore due to a hostile regulatory environment and that SEC Chair Gary Gensler’s enforcement-first approach could stifle innovation in the industry.
The NFA approval, which came nearly two years after Coinbase filed its application, could allow the company to expand into a largely untapped market.
The global derivatives market represents almost 80% of the entire crypto market, with leveraged bets on futures and other derivatives often at the root of volatility in the wider market.
In July, crypto derivatives trading volumes globally totaled about $1.85 trillion, according to research firm CCData.
Source : Reuters
Christian Mumssen, the fund's new director of strategy, cited a rapid succession of major shocks…
Gold bounces from two-week low, markets await US inflation data. Gold ticked higher on Tuesday…
Reuters poll forecasts U.S. headline inflation at 3.8%. The dollar remained in sight of 13-month…
When Credit Suisse failed in March 2023, Swiss authorities, against market expectations, set aside the…
US labour productivity has accelerated since 2022. Output per hour grew around 2.5% per year…
Europe pays for innovative medicines through 27 uncoordinated national negotiations, generating access delays, cross-country pricing…